Alectnib for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
Taichung Veterans General Hospital, Xitun Dist., TaiwanNon-Small Cell Lung CancerAlectnib - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: From the date of randomization until death due to any cause up to approximately 8 years

Year 8
Overall Survival (OS)
Year 5
Year 2
Percentage of Participants with Adverse Advent
Week 3
Plasma Concentration of Alectinib
Plasma Concentration of Alectinib metabolite

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Platinum-Based Chemotherapy
1 of 2
1 of 2

Active Control

Experimental Treatment

257 Total Participants · 2 Treatment Groups

Primary Treatment: Alectnib · No Placebo Group · Phase 3

Experimental Group · 1 Intervention: Alectnib · Intervention Types: Drug
Platinum-Based ChemotherapyActiveComparator Group · 5 Interventions: Pemetrexed, Cisplatin, Vinorelbine, Gemcitabine, Carboplatin · Intervention Types: Drug, Drug, Drug, Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from the date of randomization until death due to any cause up to approximately 8 years

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,374 Previous Clinical Trials
1,068,656 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,155 Previous Clinical Trials
876,532 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
If you're a man, you must agree to use contraception or remain abstinent during the study period, and avoid donating sperm for at least 90 days after the last dose of alectinib or chemotherapy as per local guidelines.

Frequently Asked Questions

Are researchers presently recruiting study participants?

"Unfortunately, this specific clinical trial is no longer actively recruiting patients. The trial was initially posted on 8/16/2018 but was last edited on 8/10/2022. If you are interested in other trials, there are 1390 clinical trials for patients with carcinoma, non-small-cell lung and 1518 trials for Alectnib currently looking for patients." - Anonymous Online Contributor

Unverified Answer

How many people are approved to participate in this experiment?

"Unfortunately, this study is not currently recruiting patients. The trial began on August 16th, 2018 and concluded on August 10th, 2020. There are other ongoing studies that may be of interest; as of now, there are 1390 trials enrolling patients with non-small-cell lung carcinoma and 1518 trials enrolling patients for Alectinib." - Anonymous Online Contributor

Unverified Answer

What are Alectinib's common applications in medicine?

"Alectinib, while most commonly used to treat lymphoma, can also be used as a line of defense against non-hodgkin, recurrent cervical cancer, and locally advanced non-small cell lung cancer." - Anonymous Online Contributor

Unverified Answer

Do patients experience many side effects while taking Alectinib?

"Alectinib has received a score of 3 for safety. This is due to the Phase 3 status of the drug, meaning that there is both efficacy data as well as multiple rounds of safety data." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.